The most crucial factor is size: conformational structure, targeted size (1 and 200 nm), high drug loading efficiency, a long half-life in circulation with minimal systemic toxicity, selective localization, and high adhesion in the tumour environment (97)
Compounded medications are not FDA approved and carry risks related to inconsistent potency, sterility, and formulation quality
As clinicians, weve seen it time and again, especially during the first few months on GLP-1 medications, such as semaglutide or tirzepatide
Accurate a well-established cardiovascular benefit
This is a proposed rule, not a final one - but the direction is unambiguous
Pollard et al , 1998